About Intellectual Property IP Training Respect for IP IP Outreach IP for… IP and... IP in... Patent & Technology Information Trademark Information Industrial Design Information Geographical Indication Information Plant Variety Information (UPOV) IP Laws, Treaties & Judgements IP Resources IP Reports Patent Protection Trademark Protection Industrial Design Protection Geographical Indication Protection Plant Variety Protection (UPOV) IP Dispute Resolution IP Office Business Solutions Paying for IP Services Negotiation & Decision-Making Development Cooperation Innovation Support Public-Private Partnerships AI Tools & Services The Organization Working with WIPO Accountability Patents Trademarks Industrial Designs Geographical Indications Copyright Trade Secrets WIPO Academy Workshops & Seminars IP Enforcement WIPO ALERT Raising Awareness World IP Day WIPO Magazine Case Studies & Success Stories IP News WIPO Awards Business Universities Indigenous Peoples Judiciaries Genetic Resources, Traditional Knowledge and Traditional Cultural Expressions Economics Gender Equality Global Health Climate Change Competition Policy Sustainable Development Goals Frontier Technologies Mobile Applications Sports Tourism PATENTSCOPE Patent Analytics International Patent Classification ARDI – Research for Innovation ASPI – Specialized Patent Information Global Brand Database Madrid Monitor Article 6ter Express Database Nice Classification Vienna Classification Global Design Database International Designs Bulletin Hague Express Database Locarno Classification Lisbon Express Database Global Brand Database for GIs PLUTO Plant Variety Database GENIE Database WIPO-Administered Treaties WIPO Lex - IP Laws, Treaties & Judgments WIPO Standards IP Statistics WIPO Pearl (Terminology) WIPO Publications Country IP Profiles WIPO Knowledge Center WIPO Technology Trends Global Innovation Index World Intellectual Property Report PCT – The International Patent System ePCT Budapest – The International Microorganism Deposit System Madrid – The International Trademark System eMadrid Article 6ter (armorial bearings, flags, state emblems) Hague – The International Design System eHague Lisbon – The International System of Appellations of Origin and Geographical Indications eLisbon UPOV PRISMA UPOV e-PVP Administration UPOV e-PVP DUS Exchange Mediation Arbitration Expert Determination Domain Name Disputes Centralized Access to Search and Examination (CASE) Digital Access Service (DAS) WIPO Pay Current Account at WIPO WIPO Assemblies Standing Committees Calendar of Meetings WIPO Webcast WIPO Official Documents Development Agenda Technical Assistance IP Training Institutions COVID-19 Support National IP Strategies Policy & Legislative Advice Cooperation Hub Technology and Innovation Support Centers (TISC) Technology Transfer Inventor Assistance Program WIPO GREEN WIPO's Pat-INFORMED Accessible Books Consortium WIPO for Creators WIPO Translate Speech-to-Text Classification Assistant Member States Observers Director General Activities by Unit External Offices Job Vacancies Procurement Results & Budget Financial Reporting Oversight
Arabic English Spanish French Russian Chinese
Laws Treaties Judgments Browse By Jurisdiction

Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301 et seq., United States of America

Back

Superseded Text  Go to latest Version in WIPO Lex
Year of Version 2004 Dates Amended up to: January 6, 2020 Type of Text IP-related Laws Subject Matter Patents (Inventions), Competition, Undisclosed Information (Trade Secrets), Enforcement of IP and Related Laws, Transfer of Technology Notes Originally passed by Congress in 1938, the FD&C Act is a set of laws giving authority to the U.S. Food and Drug Administration (FDA) to oversee the safety and efficacy of food, drugs, and cosmetics. Since then, the FD&C Act has been amended numerous times, including by the Drug Price Competition and Patent Term Restoration Act (a.k.a. the Hatch-Waxman Act) of 1984. This federal law set forth a process by which producers of generic drugs can file Abbreviated New Drug Applications (ANDAs) to seek FDA approval before the patent protection period has expired for the branded counterpart (see Chapter V, Subchapter A - ‘New Drugs,’ section 505(j) (21 U.S.C. 355(j)). Also, first-to-file ANDA holders are granted 180 days of generic exclusivity (see Chapter V, Subchapter A - ‘New Drugs,’ section 505(j)(5)(B)(iv)).

Please note that section 505 appears in the U.S. Code as section number 21 U.S.C 355.

Implementing regulations can be found in the Code of Federal Regulations Title 21.


Available Texts Main text(s) Main text(s) English Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301 et seq. PDF HTML
Legislation Is amended by (1 text(s)) Is amended by (1 text(s))
Food and Drug Administration Amendments Act of 2007 (Public Law 110-85, 121 Stat. 823) (US201)
Is implemented by (1 text(s)) Is implemented by (1 text(s))
Code of Federal Regulations, Title 19, Customs Duties (Revised as of April 1, 2012) (US321)
Is superseded by (1 text(s)) Is superseded by (1 text(s))
Section 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.§ 355 (US217)


WIPO Lex No. US200